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The human genome encodes instructions for the regulation of gene 
expression, which varies both across cell types and across individuals. 
Recent large-scale studies have characterized the regulatory function 
of the genome across a diverse array of cell types, each from a small 
number of samples1–3. Measuring how gene regulation and expression 
vary across individuals has further expanded our understanding of 
the functions of healthy tissues and the molecular origins of complex 
traits and diseases4–9. However, these studies have been conducted in 
limited, accessible cell types, thus restricting the utility of these studies 
in informing regulatory biology and human health.
The Genotype-Tissue Expression (GTEx) project was established 
to characterize human transcriptomes within and across individuals 
for a wide variety of primary tissues and cell types. Here, we report on 
a major expansion of the GTEx project that includes publicly availa-
ble genotype, gene expression, histological and clinical data for 449 
human donors across 44 (42 distinct) tissues. This enables the study of 
tissue-specific gene expression and the identification of genetic asso-
ciations with gene expression levels (expression quantitative trait loci, 
or eQTLs) across many tissues, including both local (cis-eQTLs) and 
distal (trans-eQTLs) effects.
In this study, we associate genetic variants with gene expression levels 
from the GTEx v6p release. We found pervasive cis-eQTLs, which affect 
the majority of human genes. In addition, we identify trans-eQTLs 
across 18 tissues and highlight their increased tissue specificity relative 
to cis-eQTLs. We evaluate both cis- and trans-eQTLs with respect to 
their functional characteristics, genomic context, and relationship to 
disease-associated variation.
Study design
The GTEx project has created a reference resource of gene expression 
levels from ‘normal’, non-diseased tissues. Every tissue sample was 
examined histologically; the sample was accepted for the project if 
the tissue was non-diseased and in the normal range for the age of 
the donor. RNA was isolated from postmortem samples in an ongoing 
manner as donors were enrolled into the study. For this data release, 
44 sampled regions or cell lines were considered, each from at least 70 
donors, and thereby considered suitable for eQTL analysis: 31 solid- 
organ tissues, 10 brain subregions including duplicates of two regions 
Characterization of the molecular function of the human genome and its variation across individuals is essential for 
identifying the cellular mechanisms that underlie human genetic traits and diseases. The Genotype-Tissue Expression 
(GTEx) project aims to characterize variation in gene expression levels across individuals and diverse tissues of the 
human body, many of which are not easily accessible. Here we describe genetic effects on gene expression levels across 
44 human tissues. We find that local genetic variation affects gene expression levels for the majority of genes, and we 
further identify inter-chromosomal genetic effects for 93 genes and 112 loci. On the basis of the identified genetic effects, 
we characterize patterns of tissue specificity, compare local and distal effects, and evaluate the functional properties 
of the genetic effects. We also demonstrate that multi-tissue, multi-individual data can be used to identify genes and 
pathways affected by human disease-associated variation, enabling a mechanistic interpretation of gene regulation and 
the genetic basis of disease.
(cortex and cerebellum), whole blood, and two cell lines derived from 
donor blood and skin samples. We hereafter refer to these tissues, 
regions, and cell lines as the ‘tissues’ used in eQTL analysis. A total 
of 7,051 samples from 449 donors represent the GTEx v6p analysis 
freeze (Fig. 1a; Supplementary Information 1–5; Supplementary 
Figs 1–6; Supplementary Tables 1–10). RNA sequencing (RNA-seq) 
samples were sequenced to a median depth of 78 million reads. This 
is 4.3 times more samples than reported in the GTEx pilot phase10. 
DNA was genotyped at 2.2 million sites and imputed to 12.5 million 
sites (11.5 million autosomal and 1 million X chromosome sites) using 
the multi-ethnic reference panel from 1000 Genomes Project Phase 
1 v311. Sampled donors were 83.7% European American and 15.1% 
African American. Whole-genome sequencing was performed for 
148 donors to a mean coverage greater than 30× , and all donors were 
exome-sequenced to a mean coverage over captured exons of 80× . The 
resulting data provide the deepest survey of individual- and tissue- 
specific gene expression to date, enabling a comprehensive view of 
the impact of genetic variation on gene expression levels. All data are 
available from dbGaP (accession phs000424.v6.p1) with multiple data 
views publicly available from the GTEx Portal (www.gtexportal.org).
Expression QTLs across human tissues
We identified associations between the expression levels of all expressed 
genes (eGenes) and genetic variants (eVariants) located within 1 Mb 
of the target gene’s transcription start site (TSS), which we refer to as 
cis-eQTLs for convenience, without requiring evidence of allelic effects 
at each locus. However, the majority of cis-eQTLs do exhibit allele spe-
cific expression. We applied a linear model controlling for ancestry, 
sex, genotyping platform and latent factors12 in the expression data 
for each tissue that may reflect batch or other technical variables (see 
Methods; Extended Data Fig. 1, Supplementary Information 6 and 
Supplementary Figs 7–10). Considering all tissues, we found a total 
of 152,869 cis-eQTLs for 19,725 genes, representing 50.3% and 86.1% 
of all known autosomal long intergenic noncoding RNA (lincRNA) 
and protein-coding genes, respectively (Fig. 1a, b). We identified a 
median of 2,816 autosomal protein-coding or lincRNA eGenes at a 5% 
false discovery rate (FDR) within each tissue (Extended Data Fig. 2a). 
Protein-coding genes without a cis-eQTL in any tissue were more 
OPEN
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likely to be expressed at low levels or loss-of-function intolerant 
and were enriched for functions related to development and envi-
ronmental response, indicating specific contexts in which addi-
tional eQTLs may be identified (Extended Data Fig. 3). To identify 
cis-eGenes affected by more than one functional regulatory variant, 
we applied forward–backward stepwise regression (see Methods). 
This approach identified an additional 24,886 secondary cis-eQTLs, 
with 41.2% of protein-coding genes and 24.8% of lincRNAs having 
multiple, conditionally independent eVariants in at least one tissue 
(Supplementary Fig. 11).
To identify trans-eQTLs, we tested for association between every 
protein-coding or lincRNA gene and all autosomal variants where 
the gene and variant were on different chromosomes. To minimize 
false positives in trans-eQTL detection, we controlled for the same 
observed and inferred confounders as in the cis-eQTL analysis, and 
further removed genes with poor mappability, variants in repetitive 
regions, and trans-eQTLs between pairs of genomic loci with evidence 
of RNA-seq read cross-mapping due to sequence similarity. Applying 
this approach, we identified 673 trans-eQTLs at a 10% genome-wide 
FDR. This includes 112 distinct loci (R2 ≤ 0.2) and 93 unique genes (94 
total gene associations, including a trans-eGene detected in both testis 
and thyroid) in 16 tissues (Extended Data Table 1, Extended Data 
Fig. 2b, Supplementary Information 7, 8, Supplementary Figs 12–15 and 
Supplementary Table 11). An alternative approach to quantifying FDR 
at the gene level (Supplementary Information 8 and Supplementary 
Table 12) identified 46 genes at 10% FDR, with estimated q values of 
less than 0.4 for all 94 gene associations identified using the genome-
wide FDR16. By investigating long-range intra-chromosomal eQTLs 
(≥ 5 Mb from the TSS), we discovered an additional 33 eGenes (10% 
FDR; Extended Data Table 2 and Supplementary Information 9). We 
found decaying support for cis-regulation (or interaction between cis- 
and trans-effects) over increased genomic distances based on evidence 
of allelic effects (Extended Data Fig. 4). Evidence of cis-regulation 
fell below background levels between 0.85 and 1.3 Mb from the TSS, 
empirically supporting the conventional distance threshold of 1 Mb for 
cis-eQTL detection.
As expected, sample size greatly affects eQTL mapping. Discovery 
of eGenes increased with sample size with no evidence of saturation at 
the full sample size for each tissue (Fig. 1c). The tissue with the highest 
number of identified cis-eGenes was tibial nerve, with 8,087 eGenes in 
256 samples. Testis had the most trans-eGenes, with 35 eGenes in 157 
samples (Fig. 1d), consistent with the elevated number of expressed 
genes (16,853 protein-coding genes and 4,362 lincRNA genes) and cis-
eGenes (6,796 genes). Continued discovery of eGenes with increasing 
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Figure 1 | Sample size and eGene discovery in the GTEx v6p study. 
a, Illustration of the 44 tissues and cell lines included in the GTEx 
v6p project with the associated number of cis- (left) and trans-eGenes 
(right) and sample sizes. Each tissue has a unique colour code (defined 
in Supplementary Fig. 5). b, Fraction of genes that are eGenes across all 
tissues by transcript class. The three tissues highlighted are: testis, which 
has the highest proportion of trans-eGenes; skeletal muscle, which has the 
largest sample size; and fibroblasts, which have the highest proportion of 
cis-eGenes. Dark bars depict the fraction of all curated human genes in 
GENCODE v19. Light bars depict the fraction of genes expressed in one or 
more tissues. c, Proportion of expressed genes that are cis-eGenes (y-axis) 
as a function of tissue sample size (x-axis). Colours represent tissues, as in 
a. d, Number of trans-eQTLs (x-axis) per tissue (y-axis), with sample size 
indicated by point size.
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sample size suggests that the expression of nearly all genes is influ-
enced by genetic variation (Extended Data Fig. 5a, b). We further 
observed that, for sub-sampled data ranging from 70 to 250 donors, 
sample size was a more significant contributor than additional tissues 
to the discovery of novel cis-eGenes (Extended Data Fig. 5c). For trans-
eQTL mapping, we used informed subsets of variants to reduce the 
number of tests by one to three orders of magnitude (Supplementary 
Information 10 and Supplementary Table 13). We found statistical 
power to detect additional associations in these restricted tests, such 
as the test restricted to cis-eVariants. Our results indicate that ongoing 
increases in sample size will continue to yield additional eQTLs, both 
in the cis-eQTL setting, where smaller and conditionally independent 
effects will be identified, and in the trans-eQTL setting, where statistical 
power is the main limitation.
Allele-specific expression across human tissues
The effect of cis-regulatory variation can also be quantified by allele- 
specific expression (ASE) analyses obtained by measuring the allelic 
imbalance of RNA-seq reads at transcribed heterozygous sites. A large-
scale, multi-tissue resource of ASE estimates complements eQTL map-
ping by providing access to individual-specific effects, which assists 
in the interpretation of rare variants, somatic mutations and patterns 
of imprinting8,13,14. We measured ASE at more than 135 million sites 
across tissues and donors, with a median of over 10,000 genes quan-
tified per donor (Supplementary Information 11 and Supplementary 
Fig. 16). In total, 63% of all protein-coding genes could be tested for 
ASE in at least one donor and tissue, with 54% exhibiting significant 
allelic imbalance (binomial test, 5% FDR, |effect size| ≥ 1, Extended 
Data Fig. 6a). Overall, 88% of testable genes had significant allelic 
imbalance in at least one donor (binomial test, 5% FDR), demonstrat-
ing an abundance of cis-linked regulatory effects. Per donor, a median 
of 1,963 genes had significant allelic imbalance in at least one tissue, 
with a median of 570 genes where the donor was not heterozygous for 
a top eVariant, suggesting more complex or rarer regulatory effects at 
these loci.
Tissue-sharing and specificity of eQTLs
The extensive and diverse tissue sampling allowed us to develop a 
global view of how genetic effects vary between tissues of the human 
body by evaluating the sharing of eQTLs across tissues. We performed 
a meta-analysis across all 44 tissues for both cis- and trans-eQTLs 
to assess eQTL sharing between tissues. To do so, we applied Meta-
Tissue15, a linear mixed model that allows for heterogeneity in effect 
sizes across tissues and controls for correlated expression measure-
ments that result from collecting multiple tissues from the same 
donors. For each eQTL, we estimated the posterior probability that the 
effect is shared in each tissue (m value). For both cis- and trans-eQTLs, 
we observed patterns that reflected relationships between related 
tissues and concordance between cis and trans in estimates of tissue 
similarity (Fig. 2a, Supplementary Information 12 and Supplementary 
Fig. 17). The strongest broad pattern observed was the high corre-
lation among brain tissues (median Spearman’s ρ of 0.584 (cis) and 
0.241 (trans)) and among non-brain tissues (median Spearman’s ρ of 
0.606 (cis) and 0.165 (trans)), with much lower correlation observed 
between these two groups (median Spearman’s ρ of 0.499 (cis) and 
0.096 (trans)). Within non-brain tissues, we observed strong corre-
lation among closely related tissues, such as arterial tissues (median 
Spearman’s ρ of 0.743 (cis) and 0.264 (trans)), skeletal muscle and 
heart tissues (median Spearman’s ρ of 0.672 (cis) and 0.184 (trans)), 
and skin tissues (Spearman’s ρ of 0.804 (cis) and 0.365 (trans)). Overall, 
the median pairwise correlation between tissues was 0.547 (cis) and 
0.138 (trans).
The patterns of sharing were also supported by replication between 
single-tissue cis-eQTLs, estimated by π1 (the proportion of true posi-
tives16) among the eQTLs identified in one tissue and then tested 
for replication in a second tissue (Extended Data Fig. 7a, median 
π1 = 0.740). The patterns held even when accounting for variable num-
ber of overlapping donors among pairs of tissues in the GTEx study 
design (Extended Data Fig. 7b–e). cis-eQTLs exhibited a distinctly 
bimodal pattern of tissue sharing—they were likely to be either shared 
across most of the 44 tissues or specific to a small subset of tissues 
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Figure 2 | Patterns of tissue sharing of eQTL effects. a, Similarity 
(Spearman’s ρ) of Meta-Tissue effect sizes between tissues for cis- (upper 
triangle, 5% FDR) and trans- (lower triangle, 50% FDR) eQTLs. Tissues 
(by colours as in Fig. 1a) are ordered by agglomerative hierarchical 
clustering of the cis-eQTL results. b, The number of tissues in which a 
given eQTL is shared as a function of tissue sample size. For each tissue, 
we estimated the degree of sharing (number of tissues with m > 0.9) for 
all eQTLs identified in that tissue at a 5% FDR. Tissues were then binned 
into quartiles on the basis of sample size. A higher proportion of eQTLs 
identified in tissues with small sample sizes have shared effects across 
multiple tissues compared with more deeply sampled tissues. This pattern 
inverts at higher sample sizes where more of the effects are tissue-specific. 
The median number of shared tissues is plotted for each quartile as a 
horizontal black line. c, Distribution of the number of tissues having Meta-
Tissue m > 0.5 for the top variant for each trans-eGene at 50% FDR, and 
FDR-matched, randomly selected cis-eGenes (also 50% FDR). cis-eGenes 
were matched for discovery tissue to the trans-eGenes.
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(Fig. 2b). This bimodality was further supported by three different 
methods: simple overlap of the single tissue eQTLs, a hierarchical mul-
tiple comparison procedure (treeQTL17), and an empirical Bayes model 
(MT-eQTL18; Extended Data Fig. 8a–c). Each method also demon-
strated that cis-eQTLs discovered in tissues with larger sample sizes 
were more often tissue-specific; however, estimates of tissue-specificity 
for large sample-size tissues can be influenced by difficulty in replicat-
ing small effect-size eQTLs in tissues with fewer samples.
Overall, we observed much greater tissue specificity for trans-eQTLs 
than a set of FDR-matched cis-eQTLs (Fig. 2c); this observation was 
robust to choices of m value threshold and selection criteria for match-
ing cis-eQTLs (Extended Data Fig. 8d–g). While 3.8% of trans-eQTLs 
were shared across three or more tissues at m > 0.9, 25.3% of FDR-
matched cis-eQTLs were shared. The extensive tissue-specificity of 
trans-eQTLs was also supported by a hierarchical approach for FDR 
control17, where we found no trans-eQTLs shared across more than 
one tissue (Extended Data Table 3). Our estimate of increased tissue 
specificity for trans-eQTLs agreed with the minimal sharing of trans 
effects reported in previous eQTL studies with fewer tissues4,19, and 
greatly exceeds what would be expected on the basis of replication 
between tissues for cis-eQTLs of matched minor allele frequency 
(MAF) and effect size (Wilcoxon rank sum test; P ≤ 2.2 × 10−16 for all 
choices of replication FDR; Extended Data Fig. 8h). Given the greater 
tissue-specificity of trans-eQTLs, we note that heterogeneity in cellular 
composition of bulk tissue samples is one important confounder that 
may reduce power to detect trans-eQTLs, or even lead to false positive 
associations6. Despite the high tissue-specificity, we did observe a small 
number of tissue-shared trans-eQTLs, including rs7683255, which was 
moderately associated in trans with NUDT13 across most tested GTEx 
tissues with a consistent direction of effect (Extended Data Fig. 9a). We 
also found examples of trans-eQTLs shared across a subset of related 
tissues, such as an association between rs60413914 and RMDN3, a gene 
with increased expression levels in brain regions as compared to other 
tissue types, and for which the trans-eQTL had moderate effects in 
all tested brain regions but no strong effect in other tissues (Extended 
Data Fig. 9b, c).
Multi-tissue cis-eQTL analyses have been shown to increase power 
by explicitly modelling sharing patterns across tissues15,18,20. We did not 
observe an improvement in power for trans-eQTL discovery, consistent 
with the limited sharing observed across tissues (Extended Data Table 3). 
However, we did observe improvements for cis-eQTL discovery, 
particularly among tissues with smaller sample sizes (Extended Data 
Fig. 10). To ensure that these findings did not depend on the modelling 
assumptions of Meta-Tissue, we analysed the P values for all genes and 
all tissues with treeQTL, which controls the FDR of eGene discoveries 
across tissues17. This procedure identified 17,411 cis-eGenes at 5% FDR, 
2,314 fewer eGenes than with the single-tissue analysis. Although this 
analysis is more conservative overall than the tissue-by-tissue analy-
sis, we observed an increase in the number of eGenes detected in the 
tissues with the smallest sample sizes, including several brain regions, 
as well as an increase in the average number of tissues in which an 
eGene was detected (from 7.8 for single-tissue analysis to 8.3; Extended 
Data Fig. 10). Additional cis-eGenes identified through meta-analysis 
were more likely to be significant as sample size increased compared 
to similar numbers of eGenes identified using a less stringent single- 
tissue FDR (Extended Data Fig. 10). This suggests that one strategy for 
increasing power in studies of inaccessible or sample-limited cell types 
would be to analyse them jointly with data from GTEx tissues.
Functional characterization of cis-eQTLs
To characterize the biological properties of multi-tissue cis-eQTLs, 
we annotated discovered eVariants using chromatin state predictions 
from 128 cell types sampled by the Roadmap Epigenomics project2. 
eVariants were enriched in predicted promoter and enhancer states 
across all Roadmap cell types (Fig. 3a). However, the eVariants exhib-
ited signifi cantly greater enrichment in promoters and enhancers from 
matched tissues (Wilcoxon rank sum test, P ≤ 9.3 × 10−4, Extended 
Data Table 4), illustrating consistent patterns of tissue specificity for 
cis-regulatory elements and eQTLs (Fig. 3a). Furthermore, eQTL activ-
ity was significantly more likely to be shared across pairs of tissues 
when the eVariant overlaps the same chromatin state in both tissues 
(Wilcoxon rank sum test, P ≤ 5.0 × 10−5, Fig. 3b).
Integration of genomic annotations such as chromatin state has been 
demonstrated to improve power for eQTL discovery8,21–23. For 26 GTEx 
tissues matched with cell-type specific annotations from the Roadmap 
Epigenomics project, we applied a Bayesian hierarchical model for 
eQTL discovery by incorporating variant-level genomic annotations24 
that provided a substantial boost to discovery power. Inclusion of 
genomic annotations (enhancers, promoters and distance to the TSS) 
increased the total number of cis-eQTL discoveries by an average of 
43% (or 1,200 genes) per tissue (Extended Data Fig. 10f), demonstrat-
ing the considerable advantage of integrating genomic annotations into 
eQTL mapping models.
Conditionally independent (secondary) cis-eQTL signals were 
located further from the TSS (median distance 50.1 kb from the TSS, 
compared to 28.9 kb for primary eQTLs; Wilcoxon rank sum test, 
P ≤ 2.2 × 10−16). However, similar to primary eVariant associations, 
secondary eVariants were enriched for chromosomal contact with 
target eGene promoters, as determined through Hi-C, compared to 
background variant–TSS pairs (Supplementary Information 6). This 
suggests that, despite their sequence-based distance from the TSS, 
primary and secondary eVariants are in close physical contact with 
their target gene promoters via chromatin looping interactions. While 
primary eVariants were significantly more enriched in promoters 
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Figure 3 | Functional characterization of cis-eQTLs. a, Enrichment  
(x-axis) of eVariants in cis-regulatory elements (CREs) across 128 Roadmap 
Epigenomics project cell types, for each GTEx discovery tissue (y-axis). 
Enrichment estimated by comparing to random MAF- and distance-
matched variants. Stronger enrichment was observed in matched tissues 
(coloured dots) than in unmatched tissues (box plots). b, Proportion of 
eQTLs shared between two tissues (m > 0.9) if the eVariant overlaps the 
same Roadmap annotation in both tissues (y-axis) or different annotations 
(x-axis). Points represent the mean across all tissues, coloured by the 
discovery tissue. c, Enrichment of eVariants (y-axis) in tissue-matched 
enhancers (black) and promoters (grey) for the first four conditionally 
independent eQTLs discovered for each eGene (x-axis). d, Proportion of 
eVariants overlapping tissue-matched DNase I hypersensitive sites (DHS;  
y-axis) as a function of the probability that a variant is causal (x-axis),  
coloured by the eQTL discovery tissue. e, Normalized absolute eQTL effect  
size (x-axis) for each eVariant annotation class (y-axis). f, Median (line)  
and interquartile range (shading) of normalized absolute eQTL effect size  
(y-axis), as a function of the number of tissues in which the eGene is 
expressed (x-axis). Box plots depict the interquartile range (IQR), whiskers 
depict 1.5× IQR. OR, odds ratio.
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than enhancers, secondary associations exhibit increased enhancer 
enrichment, consistent with their increased distance from the TSS 
and tissue-restricted activity (Wilcoxon rank sum test, P ≤ 2.2 × 10−16, 
Fig. 3c).
To identify causal variants that are likely to underlie cis-eQTLs, we 
applied two computational fine-mapping strategies25,26 (Supplementary 
Information 13 and Supplementary Figs 11, 18). First, we identified 
90% credible sets (that is, the collection of variants with 90% probability 
of containing all causal variants) for each eGene in each tissue using 
CAVIAR25. Across all tissues, the mean credible set size was 29 variants 
(per tissue means ranged from 25 to 31). Second, we estimated the 
probability that each eVariant is a causal variant using CaVEMaN26. 
Across tissues, between 3.5% and 11.7% of top eVariants were predicted 
to be causal variants (causal probability P > 0.8). Consistent with vari-
ants with high causal probabilities being functional regulatory variants 
(as opposed to linkage disequilibrium proxies), 24.3% of eVariants with 
causal probabilities in the top tenth percentile (0.77 < P < 1) lay in open 
chromatin regions, while only 6.56% of eVariants in the lowest tenth 
percentile (0.0266 < P < 0.189) lay in such regions (Fig. 3d).
To determine the effect sizes of cis-eQTLs, we used allelic fold 
change, a method that assumes an additive model of eQTL alleles on 
total gene expression, allowing for interpretation of effect sizes as a 
fold change between alleles27 (Supplementary Information 14). 17.4% 
of eGenes had cis-eQTLs with median effect sizes of at least twofold 
across tissues (Extended Data Fig. 11a, c). The prevalence of many 
≥ twofold effects highlights the large impacts that common regulatory 
variants can have on gene dosage. cis-eVariants at canonical splice sites 
exhibited the strongest effects, followed by variants in noncoding tran-
scripts, while variants in the 3′ UTR had the weakest effects (Fig. 3e).
Analysis of eQTL effect sizes around the TSS demonstrated that, as a 
group, upstream variants had the strongest effects, while those within 
transcripts had the weakest effects (Extended Data Fig. 11b). This sug-
gests that eVariants that are likely to affect transcription have stronger 
effects on gene expression levels than variants that are likely to affect 
post-transcriptional regulation of mRNA levels. A notable exception 
is splice site and stop-gained variants, which make up a small number 
of total eQTLs but have large effects on expression levels (presuma-
bly owing to nonsense-mediated decay). When genes are stratified by 
the number of tissues in which they are expressed, the average effect 
size decreases as the number of tissues increases, indicating that genes 
expressed in greater numbers of tissues are less likely to have eQTLs 
with large regulatory effects (Spearman’s ρ = − 0.29, P ≤ 2.2 × 10−16; 
Fig. 3f).
ASE provides an independent measure of a cis-eVariant’s effect size. 
We estimated the effects of the primary eVariant for each eGene by 
applying allelic fold change to ASE measurements (see Methods). Effect 
size estimates from both total and allele-specific expression approaches 
were highly correlated (mean Spearman’s ρ = 0.82, s.d. = 2%) with an 
average ratio of eQTL effect sizes to ASE effect sizes of 0.937 (s.d. = 6%; 
Extended Data Fig. 6b, c). This observation suggests that cis-eQTLs and 
ASE capture the same regulatory effects.
Functional characterization of trans-eQTLs
To better understand the cellular mechanisms of trans-eQTLs, we char-
acterized several of their functional properties. Of the 673 trans-eQTLs 
from the genome-wide analysis, 161 also had a cis-association (at a cis P 
value threshold of P ≤ 1.0 × 10−5) with 113 unique variants, yielding the 
set of 296 unique trios of an eVariant, a cis-eGene and a trans-eGene. 
This suggests a common mechanism for trans regulation in which the 
eVariant directly regulates expression of a nearby gene whose protein 
product then affects other genes downstream. Considering this obser-
vation, we ran a restricted test for trans-associations, limiting variants 
to the set of significant cis-eVariants (Extended Data Fig. 12a). From 
this, we identified a total of 33 trans-eGenes (10% FDR) among this 
subset of tests, 14 of which were not discovered in the genome-wide 
analysis (Supplementary Information 10). There were substantially 
more trans-eQTLs at 50% FDR from this cis-eVariant restricted test 
than random variants matched for MAF and distance to TSS and strat-
ified by tissue (Cochran–Mantel–Haenszel test, P ≤ 2.2 × 10−16).
We performed Mendelian randomization on the full set of 296 trans-
eQTLs matched with a unique corresponding cis-eGene, measuring the 
causal impact of the cis-eGene on the trans-eGene, using the eVariant as 
the randomized instrumental variable (Supplementary Information 15). 
For trans-eQTLs with a cis-eGene, we observed strong evidence for 
regulation of the trans-eGene expression via the cis-eGene (Fig. 4a; 
P values ranging from P ≤ 3.0 × 10−5 to P ≤ 2.2 × 10−16). trans- 
eVariants with no cis-eGene may alter protein function, may reflect 
false negatives in the cis association test, or may arise from unmeasured 
regulatory mechanisms. Protein-coding loci were not enriched among 
our trans-eVariants (odds ratio 0.94; Fisher’s exact test, P ≤ 0.80), sug-
gesting that modification of protein function is not the dominant 
mecha nism for trans-eQTL effects.
We investigated whether trans-eVariants were each associated with 
numerous target genes, which may reflect broad effects of regulatory 
loci, as have been reported in model organisms5,28. Disambiguating 
true broad regulatory effects from artefacts remains an important chal-
lenge29. In our primary analysis, we applied aggressive correction of 
potential confounders, controlling for 15–35 probabilistic estimation 
of expression residuals (PEER) factors12 capturing 59–78% of total 
variance in gene expression levels (Supplementary Information 5). 
However, PEER and related approaches30 may also remove variance in 
gene expression levels arising from regulatory pathways and broad trans 
effects. Indeed, several loci with numerous associations were found in 
uncorrected data, but disappeared after controlling for PEER factors 
(Supplementary Fig. 13). Associations found in uncorrected data are 
likely to include many false positives for three reasons: 1) the PEER 
factors were strongly associated with known technical confounders 
(Extended Data Fig. 1 and Supplementary Figs 8, 9); 2) trans-eVari-
ants identified from raw data and lost after correction were enriched 
for association with technical covariates (Supplementary Fig. 14); and 3) 
no other parameter setting clearly optimized trans-eQTL discovery 
(Supplementary Fig. 12). Even after PEER correction, we observed evi-
dence of eVariants with multiple targets; at genome-wide significance, 
four separate loci were associated with more than one trans-eGene each 
(Supplementary Table 14).
We quantified the enrichment of trans-eVariants in promoter and 
enhancer regions using the same tissue-specific annotations from the 
Roadmap Epigenomics project1,2 used for cis-eQTL analysis (Extended 
Data Table 4). trans-eVariants (10% FDR) were enriched in cell-type 
matched enhancers (median Fisher’s exact test, P ≤ 2.2 × 10−3) but 
not strongly enriched for promoters (median P ≤ 0.22), compared to 
randomly selected variants matched by distance to nearest TSS, MAF 
and chromosome (Fig. 4b). trans-eVariants were more enriched than 
cis-eVariants at matched FDR (Wilcoxon rank sum test, promoter: 
P ≤ 4.6 × 10−7; enhancer: P ≤ 2.2 × 10−16). Stronger effect sizes are 
needed to detect trans-eVariants at the same FDR, but even compar-
ing to a matched number of the strongest cis-eVariants, we observed 
greater enrichment in enhancer (but not promoter) regions among 
trans-eVariants, consistent with greater tissue-specificity of enhancer 
activity and trans-eVariants31 (Fig. 2c).
Given the large number of trans-eQTLs detected in testis, we inves-
tigated their possible regulatory mechanisms in more detail. Piwi-
interacting RNAs (piRNAs) are small 24–31-bp RNAs that bind to 
piwi-class proteins and silence mobile elements by RNA degradation 
and DNA methylation. PiRNAs are strongly expressed in testis and 
may regulate gene expression and play a role in protection against 
transposable elements in germ line cells32. We tested for enrichment 
of trans-eVariants in piRNA clusters identified in testis33. We found 
that 38.6% of testis trans-eVariants, corresponding to 12 independent 
loci (R2 ≤ 0.2), directly overlapped piRNA clusters, a significant enrich-
ment compared to the 2.5% of the genome covered by these regions 
(permutation test, P ≤ 1.0 × 10−4). In aggregate, eVariants from 
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all tissues were enriched in piRNA clusters (permutation test, 
P ≤ 1.0 × 10−4), but this appeared to be almost entirely driven by tes-
tis eQTLs (Fig. 4c). This suggests a testis-specific functional effect of 
genetic variation in piRNA clusters, consistent with their biological role.
Replication of eQTLs
To assess the replicability of the identified cis-eQTLs, we com-
pared our results to four matched tissues from the TwinsUK 
project34 (Supplementary Information 16). The vast majority of GTEx 
cis-eQTLs replicated at 5% FDR (Extended Data Fig. 13a; 84% in 
whole blood, 87% in subcutaneous adipose, 94% in lymphoblas-
toid cell lines (LCLs), and 93% in sun-protected skin). trans-eQTLs 
have not replicated consistently in human studies, compared to cis-
eQTLs21,35–37, owing in part to insufficient statistical power and a 
limited number of studies with comparable tissues and cohorts, but 
also reflecting potential false positive associations. We tested trans-
eQTLs discovered at 10% FDR in GTEx for replication in the TwinsUK 
data. Five hundred and sixty GTEx trans-eQTLs were testable in the 
four TwinsUK tissues and, of these, three trans-eQTLs replicated 
at 10% FDR (Supplementary Table 15). Despite the small number 
that individually replicated, in aggregate, the full set of trans-eQTLs 
demonstrated significantly greater replication than expected by chance 
(Wilcoxon rank sum test on association P values compared to uni-
form; P ≤ 3.05 × 10−5 for 16 tests in matched tissues; P ≤ 2.2 × 10−16 
for 2,176 tests across all four TwinsUK tissues). In addition, aggregate 
replication of trans-eQTLs was significantly stronger for matched 
tissue types than for unmatched tissue types (Wilcoxon rank sum test; 
P ≤ 1.54 × 10−4; Extended Data Fig. 13b).
Finally, we replicated two tissue-specific trans-eQTLs highlighted in 
the TwinsUK Multiple Tissue Human Expression Resource (MuTHER) 
study38,39 (n = 845 donors in three tissues: subcutaneous adipose, LCLs 
and skin). First, in sun-exposed skin in GTEx, rs289750 was associ-
ated in cis with NLRC5 (association P ≤ 4.7 × 10−16) and in trans 
with TAP1 (association P ≤ 9.0 × 10−10, 4.3% FDR in the cis-eQTL 
restricted trans-eQTL discovery set), while the TwinsUK study found 
rs289749 (located 469 bp away from rs289750; R2 = 0.918) associ-
ated in skin samples with NLRC5 in cis (association P ≤ 2.2 × 10−16) 
(ref. 38) and TAP1 in trans (tensor association P ≤ 4.3 × 10−7) 
(ref. 39). Second, the MuTHER study identified a master regulator 
in subcutaneous adipose, rs4731702, associated with the maternally 
expressed cis target gene KLF14, which encodes the transcription factor 
Kruppel-like factor38,40. cis-eQTL rs4731702 showed enriched asso-
ciation with genes that are relevant in metabolic phenotypes, such as 
cholesterol levels. In the GTEx data, rs4731702 is in strong linkage dis-
equilibrium with two variants, rs13234269 and rs35722851 (R2 = 0.98 
and 0.99, respectively), that are cis-eQTLs for KLF14 in subcutaneous 
adipose (P ≤ 2.2 × 10−5 and P ≤ 4.7 × 10−5, respectively). We evaluated 
the association of rs13234269 with all expressed genes in GTEx sub-
cutaneous adipose (17,633 genes). Although we found no individually 
significant trans-eGenes, we found an enrichment of association with 
distal gene expression in subcutaneous adipose tissue (π1 = 0.07, after 
PEER correction), replicating the results of the MuTHER study.
Expression QTLs and complex disease associations
Overlaps between genome-wide association study (GWAS) associations 
and eQTLs have provided important insights into regulatory genes and 
variants for a wide range of complex traits and diseases5. As both the 
presence and extent of overlap between GWAS and eQTLs can be tissue- 
specific, the current phase of GTEx overcomes a major limitation in 
interpretation of disease variants by enabling analysis across a broad 
range of tissues.
We observed that the degree of tissue sharing of an eQTL is asso-
ciated with several indicators of phenotypic impact. Tissue-shared 
eGenes are depleted from loss-of-function mutation-intolerant genes 
(as curated by ExAC41) (Fig. 5a), consistent with purifying selection 
removing large-effect regulatory variants that involve many tissues. 
Tissue-shared eGenes were also less likely than tissue-specific 
eGenes to be annotated disease genes (Fisher’s exact test, nominal 
P ≤ 10−6 for GWAS, Online Mendelian Inheritance in Man (OMIM), 
and loss-of-function-intolerant gene sets; Fig. 5a, Extended Data 
Fig. 14), highlighting the importance of broad tissue sampling for 
GWAS interpretation.
This broad tissue sampling affects the use of eQTL data for the 
interpretation of GWAS variants. We observed that a GWAS variant 
of interest is likely to be a cis-eQTL by chance. Of all common variants 
assayed within GTEx, 92.7% are nominally associated with the expres-
sion of one or more genes in one or more tissues (P < 0.05) and nearly 
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Figure 5 | Properties of cis-eQTL overlap with complex trait associated 
loci. a, Enrichment of tissue-specific and tissue-shared eGenes in disease 
and loss-of-function mutation intolerant genes. Tissue-specific and 
shared eGenes were defined as eGenes in the bottom and top 10% of the 
distribution of proportion of tissues with an eQTL effect. Bars represent 
95% confidence intervals. b, Proportion of eQTLs (y-axis) discovered 
as a function of P cutoffs (x-axis). c, Proportion of variants (y-axis) with 
top associated protein-coding gene shared between tissues at varying 
P thresholds (x-axis). d, Number of GWAS loci (y-axis) and their co-
localization results for each of 21 traits (x-axis), coloured by whether 
the eGene is the closest expressed gene to the lead GWAS variant. e, 
Proportion of GWAS loci (y-axis) with a significant co-localization for 
each of 21 traits (x-axis). Box plots depict the proportion explained in each 
of 44 tissues, red dots depict the proportion explained by the union of all 
tissues. Box plots depict the IQR, whiskers depict 1.5× IQR.
© 2017 Macmillan Publishers Limited, part of Springer Nature. All rights reserved.
2 1 0  |  N A T U R E  |  V O L  5 5 0  |  1 2  O c T O b E R  2 0 1 7
ArticlereSeArcH
50% are significant when correcting for the number of tissues tested 
(Fig. 5b). Furthermore, linking an eQTL signal to a specific gene 
becomes increasingly complicated with abundant eQTL data. Some 
variants are associated with more than 30 different nearby genes 
(Extended Data Fig. 15a). Furthermore, even restricting to strong asso-
ciations (P < 10−10 in each tissue), for over 10% of eVariants, the gene 
with the strongest association varies between tissues (Fig. 5c; Extended 
Data Fig. 15b, c). These results reinforce the need for caution when 
using eQTL data to interpret the function of GWAS variants.
To assess the extent to which GTEx cis-eQTLs are responsible for 
common phenotypic variation, we applied co-localization analysis to 
examine local linkage disequilibrium and sharing of association signals 
using GWAS summary statistics across 21 traits42–44 (Supplementary 
Table 16). Among tested loci, 52% of trait-associated variants co- 
localized with an eQTL in one or more tissues (Fig. 5d, e). Importantly, 
no single tissue explained the majority of trait-associated loci, but the 
breadth of GTEx tissue sampling identified more co-localizations than 
any single tissue alone. Seven per cent and 93% of co-localizations are 
with lincRNA and protein-coding eGenes, respectively, suggesting 
that lincRNAs have a limited role in common disease pathogenesis. 
However, several findings complicate the interpretation of GWAS–
eQTL overlaps. First, 26% of GWAS loci co-localize with more than 
one distinct eGene (that is, half of all co-localized loci). Second, GWAS 
co-localized eGenes are shared across an average of four tissues. Third, 
similar to lead eVariants, only 40% of GWAS signals co-localize with 
their nearest expressed gene, a finding that has important implications 
for the functional characterization of GWAS results.
Genetic variants associated with complex traits have been suggested 
to be enriched for trans-eQTLs6,44–47. Accordingly, we performed trans-
eQTL mapping, restricting it to variants associated with a complex trait 
in a GWAS (Extended Data Fig. 12b). In this analysis, across the 44 
tissues, we found 29 trans-eQTL associations involving 24 unique 
variants and 25 unique genes (10% FDR; Fig. 4a), each specific to a 
single tissue. There were more trans-eVariants at 50% FDR with associ-
ation in at least one tissue when testing was restricted to trait-associated 
variants compared with random variants matched by MAF and distance 
to TSS (Fisher’s exact test, P ≤ 1.3 × 10−3).
Among trait-associated variants with trans-eQTL effects, we 
found two genome-wide significant trans-eVariants at the 9q22 locus 
(rs7037324 and rs1867277, R2 = 0.74) with thyroid-specific associ-
ations in trans with TMEM253 and ARFGEF3 (P ≤ 2.2 × 10−16 for 
both with rs1867277; Fig. 6a and Extended Data Fig. 16). The 9q22 
locus has previously been linked to multiple thyroid-specific diseases 
including goitre, hypothyroidism and thyroid cancer48,49, and loss-of- 
function mutations in a thyroid-specific transcription factor at this 
locus, FOXE1, manifest as ectopic thyroid tissue or cleft palate in 
developing mice. However, the mechanism of any cis-effects of these 
trans-eVariants remains uncertain from the GTEx data; a post hoc 
analysis demonstrated that PEER correction removed broad regulatory 
signals from the 9q22 locus, and particularly from cis- and trans-eQTL 
signals for FOXE1 (Supplementary Information 17). In PEER-corrected 
data, cis- and trans-eQTL signals co-localized for another cis-eGene in 
9q22, TRMO, for both trans-eGenes43 (posterior probability > 0.99). 
Mendelian randomization analysis of the PEER-corrected data sup-
ported the idea that TRMO regulates TMEM253 (P ≤ 1.3 × 10−9) and 
ARFGEF3 (P ≤ 2.1 × 10−11) based on trans-eVariant rs1867277. By con-
trast, FOXE1 had weak Mendelian randomization support in the PEER-
corrected data. Despite the ambiguity of cis-mediation, the locus is one 
of the strongest trans-eQTL signals in GTEx. We further replicated both 
the broad regulatory effect and specific target genes of this locus in 498 
primary thyroid cancer RNA-seq samples from The Cancer Genome 
Atlas50 (TCGA; Fig. 6b, Supplementary Information 18).
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Figure 6 | Characterization of complex trait-associated trans-eQTLs. 
a, Association of rs1867277 with PEER-corrected TMEM253 expression 
(P ≤ 2.2 × 10−16). b, Quantile–quantile plot of associations between 19 
variants in the 9q22 locus and all genes in GTEx thyroid gene expression 
levels, compared to 19 random variants from the same chromosome, and 
associations between 23 variants in the 9q22 locus and all genes in TCGA 
thyroid tumour expression data, compared to 23 random variants from the 
same chromosome. c, Network depicting cis and trans regulatory effects 
of rs1012793 mediated through interferon regulatory factor 1 (IRF1). 
Rs1012793 affects expression of IRF1 in cis and PSME1 and PARP10 in 
trans (box plots). IRF1 is significantly co-expressed with the trans-eGenes. 
Colours in scatter plots refer to genotype at rs1012793. d, cis and trans 
association significance of variants within 1 Mb of the IRF1 TSS in the 
chromosome 5 locus with cis-eGene IRF1 (blue) and trans-eGene PSME1 
(brown), showing concordant signal across the locus. Box plots depict the 
IQR, whiskers depict 1.5× IQR.
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In a second example, two muscle-specific trans-eVariants at the 5q31 
locus (rs2706381 and rs1012793; R2 = 0.84) were associated in trans 
with PSME1 (P ≤ 1.1 × 10−11) and PARP10 (P ≤ 7.8 × 10−10), and in 
cis with IRF1 (P ≤ 2.0 × 10−10; Fig. 6c), a transcription factor that facil-
itates regulation of the interferon-induced immune response51,52. Both 
variants are associated with circulating fibrinogen levels53 and influ-
ence muscle injury, Duchenne muscular dystrophy (DMD), multiple 
sclerosis and rheumatoid arthritis54,55, and have been shown to drive 
fibrosis in DMD, where they promote expression of IL1B and TGFB156. 
These variants were moderately associated with numerous genes in 
skeletal muscle (50 trans-eGenes at 20% FDR, assessed only among 
the three variants; Extended Data Fig. 17a). Additional candidate tar-
get genes (at 20% FDR) were enriched in multiple immune pathways 
from MsigDB57 (Extended Data Fig. 17b). Mendelian randomization 
analysis supported the idea that IRF1 regulates PSME1 (P ≤ 3.1 × 10−8) 
and PARP10 (P ≤ 1.9 × 10−7) through cis-eVariant rs2706381 with a 
consistent direction of effect (Fig. 6c). Moreover, the cis-eQTL signal 
for IRF1 co-localized with the trans-eQTL signals for both trans-eGenes 
(Fig. 6d; posterior probability > 0.99)43. Together, these results suggest 
that cis-regulatory loci affecting IRF1 are regulators of interferon-re-
sponsive inflammatory processes involving genes including PSME1 and 
PARP10, with implications for complex traits specific to muscle tissue.
Discussion
Since the initial sequencing of the human genome, extensive effort 
has been devoted to the characterization of genome function and 
phenotypic consequences of genetic variation. Describing the effects 
of genetic variation on gene expression levels across tissues is a 
critical but challenging component of this goal. Here, we describe 
advances enabled by the GTEx project v6p data, which provide a 
comprehensive survey of gene expression and the impact of genetic 
variation on gene expression across diverse human tissues. We report 
widespread cis-eQTLs in 44 tissues and trans-eQTLs in 18 tissues. 
cis-acting genetic variants tend to affect either most tissues or a small 
number of tissues. By contrast, identified trans-eQTL effects tend to 
be tissue-specific and correspondingly show greater enrichment in 
enhancer regions. By integrating GTEx data with summary statistics 
from diverse GWAS, we observed that half of complex trait- 
associated loci co-localize with a GTEx eQTL. GTEx data have already 
served as a valuable community resource for the identification of the 
tissue-specific regulatory effects underlying variants associated with 
human disease phenotypes58–61.
Additional papers from the GTEx consortium for the v6p data 
describe the impact of rare genetic variation on gene expres-
sion62, methods for analysis of transcriptome data27, the discovery 
and characterization of regulatory networks across tissues63, and 
analyses of diverse regulatory processes such as RNA editing64 and 
X-inactivation65. To enable ongoing use of the GTEx data, summa-
ry-level expression data and eQTLs across all tissues are available 
from the GTEx Portal (www.gtexportal.org), while all individual-level 
raw data have been deposited in dbGaP (accession phs000424.v6.p1).
There are both opportunities and challenges as efforts to characterize 
genome function grow in scope and scale. The discovery and charac-
terization of eQTLs in these data required careful data modelling to 
account for confounders and to characterize statistical discovery. We 
anticipate that complementary analyses with novel methods, enabled 
by the public availability of these data, may reveal additional insights. 
Despite the scope of these data, we remain underpowered to detect 
trans-eQTLs. Larger cohorts of individuals with a smaller number of 
tissues have yielded hundreds of trans-eGenes4,6,8,9, and we similarly 
expect trans-eQTL discoveries to increase with additional samples 
in the final phase of GTEx. Furthermore, some genetic effects may 
manifest only within a specific cell type, rather than an entire hetero-
geneous tissue. Both computational and experimental methods, such 
as deconvolution methods and single-cell sequencing as part of the 
proposed Human Cell Atlas and related projects, promise to improve 
resolution to identify precise cell type-specific regulatory effects66. 
Future aims of the GTEx project include increased sample size, with 
cis-eQTLs from 53 tissues across 714 donors, now available in the v7 
release, and plans to include approximately 1,000 donors in the final 
data release. Additional plans include the collection of complementary 
molecular data on subsets of samples, including epigenetic and protein 
data, with the Enhanced GTEx (eGTEx) project, enabling an increas-
ingly complete picture of epigenetic and regulatory variant diversity 
across human tissues67. We expect that the continued expansion of the 
GTEx resource, and its integration with other efforts capturing diverse 
data types, will be an essential asset for the study of gene regulatory 
mechanisms and how these contribute to human traits and diseases.
Online Content Methods, along with any additional Extended Data display items and 
Source Data, are available in the online version of the paper; references unique to 
these sections appear only in the online paper.
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METHODS
No statistical methods were used to predetermine sample size. The experiments 
were not randomized, and investigators were not blinded to allocation during 
experiments and outcome assessment.
Sample procurement. All human donors were deceased. Informed consent was 
obtained for all donors via next-of-kin consent to permit the collection and bank-
ing of de-identified tissue samples for scientific research. The research protocol 
was reviewed by Chesapeake Research Review Inc., Roswell Park Cancer Institute’s 
Office of Research Subject Protection, and the institutional review board of the 
University of Pennsylvania. Complete descriptions of the donor enrolment and 
consent process, as well as biospecimen procurement, methods, sample fixation, 
and histo-pathological review procedures, have been described previously10,67. 
In brief, whole blood was collected from each donor, along with fresh skin sam-
ples, for DNA genotyping, RNA expression, and culturing of lymphoblastoid and 
fibroblast cells, and shipped overnight to the GTEx Laboratory Data Analysis and 
Coordination Center (LDACC) at the Broad Institute. Two adjacent aliquots were 
then prepared from each sampled tissue and preserved in PAXgene tissue kits. 
One of each paired sample was embedded in paraffin (PFPE) for histopathological 
review and the second was shipped to the LDACC for processing and molecular 
analysis. Brains were collected from approximately one-third of the donors, and 
were shipped on ice to the brain bank at the University of Miami, where eleven 
brain sub-regions were sampled and flash-frozen. These samples were also shipped 
to the LDACC for processing and analysis.
All DNA genotyping was performed on blood-derived DNA samples, unless 
these were unavailable, in which case a tissue-derived DNA sample was substituted. 
RNA was extracted from all tissues and RNA sequencing was performed on all 
samples with an RNA integrity number (RIN) of 5.7 or higher and with at least 
500 ng total RNA. Nucleic acid isolation protocols and sample QC metrics applied 
are as described10 (Supplementary Information 1–5).
Data production. Non-strand specific, polyA+ selected RNA-seq libraries were 
generated using the Illumina TruSeq protocol. Libraries were sequenced to a 
median depth of 78 million 76-bp paired-end reads. RNA-seq reads were aligned 
to the human genome (hg19/GRCh37) using TopHat (v1.4) based on GENCODE 
v19 annotations. This annotation is available on the GTEx Portal (gencode.v19.
genes.v6p_model.patched_contigs.gtf.gz, available at https://www.gtexportal.org/
home/datasets). Gene-level expression was estimated as reads per kilobase of tran-
script per million mapped reads (RPKM) using RNA-SeQC on uniquely mapped, 
properly paired reads fully contained within exon boundaries and with alignment 
distances ≤ 6. Samples with fewer than 10 million mapped reads or with outlier 
expression measurements based on the D statistic were removed10.
DNA from 450 donors was genotyped using Illumina Human Omni 2.5M 
and 5M Beadchips. Genotypes were phased and imputed with SHAPEIT268 
and IMPUTE269, respectively, using multi-ethnic panel reference from 1000 
Genomes Project Phase 370. Variants were excluded from analysis if they: 1) had 
a call rate < 95%; 2) had minor allele frequencies < 1%; 3) deviated from Hardy–
Weinberg equilibrium (P < 1.0 × 10−6); or 4) had an imputation info score < 0.4. 
The final genotyped and imputed array VCF (file format v4.1) for autosomal 
variants contains genotype posterior probabilities for each of the three possible 
genotypes for 11,552,519 variants across 450 GTEx donors. The dosages of the 
alternative alleles relative to the human reference genome hg19 were used as the 
genotype measure for subsequent eQTL analysis. In addition to array-based gen-
otyping, 148 and 524 donors were whole-genome and exome sequenced, respec-
tively. Additional details on genotyping, imputation and sequencing can be found 
in the Supplementary Information.
cis-eQTL mapping. We conducted cis-eQTL mapping within the 44 tissues with 
at least 70 samples each. Only genes with ten or more donors with expression 
estimates > 0.1 RPKM and an aligned read count of six or more within each tissue 
were considered significantly expressed and used for cis-eQTL mapping. Within 
each tissue, the distribution of RPKMs in each sample was quantile-transformed 
using the average empirical distribution observed across all samples. Expression 
measurements for each gene in each tissue were subsequently transformed to the 
quantiles of the standard normal distribution. The effects of unobserved confound-
ing variables on gene expression were quantified with PEER12, run independently 
for each tissue. Fifteen PEER factors were identified for tissues with fewer than 150 
samples; 30 for tissues with sample sizes between 150 and 250; and 35 for tissues 
with more than 250 tissues. The covariates that were most consistently associated 
with PEER factors include factors related to parameters of donor death, ischaemic 
time, RIN and sequencing quality control metrics. In addition, we have observed 
that little, if any, genetic signal is present in the PEER factors (Supplementary 
Information 6).
Within each tissue, cis-eQTLs were identified by linear regression, as imple-
mented in FastQTL71, adjusting for PEER factors, sex, genotyping platform, and 
three genotype-based principal components (PCs). We restricted our search to 
variants within 1 Mb of the TSS of each gene and, in the tissue of analysis, minor 
allele frequencies ≥ 0.01 with the minor allele observed in at least 10 samples. 
Nominal P values for each variant–gene pair were estimated using a two-tailed 
t-test. The significance of the most highly associated variant per gene was deter-
mined from empirical P values, extrapolated from a Beta distribution fitted to 
adaptive permutations with the setting –permute 1000 10000. These empirical 
P values were subsequently corrected for multiple testing across genes using Storey’s 
q value method16. To identify the list of all significant variant–gene pairs associated 
with eGenes, variants with a nominal P value below the gene-level threshold were 
considered significant and included in the final list of variant–gene pairs.
trans-eQTL mapping. Matrix eQTL72 was used to test all autosomal variants 
(MAF > 0.05) using the same expression filters as cis-eQTL mapping, but restricted 
to variants and genes lying on different chromosomes, in each tissue independently 
using an additive linear model. For trans-eQTL mapping, we tested variants for 
association with expression of only protein coding or lincRNA genes. We included 
as covariates the three genotype PCs, genotyping platform, sex, and PEER factors 
estimated from expression data in Matrix eQTL when performing association test-
ing. The correlation between variant and gene expression levels was evaluated using 
the estimated t statistic from this model, and corresponding FDR was estimated 
using Benjamini–Hochberg FDR correction72,73 separately within each tissue and 
also using permutation analysis. We performed restricted trans-eQTL association 
tests by filtering the set of variants considered in three ways. First, we filtered the 
final VCF files using linkage disequilibrium pruning (R2 > 0.5, plink parameters – 
indep 50 5 2), removing approximately 90% of variants. Second, from the original 
VCF file, we performed association mapping using only the most significant GTEx 
cis-eQTL per eGene per tissue. Third, from the original VCF file, we performed 
association mapping using only variants that had been found to have a trait associ-
ation in a genome-wide association study47 (P ≤ 2.0 × 10−5). The three association 
mapping analyses and FDR estimation were performed in each tissue separately. 
For all trans association tests, we applied stringent quality control to account for 
potential false positives due to RNA-seq read mapping errors, repeat elements, and 
population stratification (Supplementary Information 7).
Multi-tissue eQTL mapping. We quantified the tissue-specificity and tissue-sharing 
of cis- and trans-eQTLs using Meta-Tissue15. This tool extends Metasoft74, a 
meta-analysis package, by using a mixed effects model for eQTL sharing that 
accounts for correlation of expression between tissues driven by overlapping 
donors. All genotypes and gene expression quantification estimates were adjusted 
for covariates in accordance to the single tissue analysis as described in the pre-
vious sections. For each variant–gene pair, we calculated mixed model effect size 
estimates in each expressed tissue, thereby adjusting for partial sharing of sig-
nal between tissues. These effect size estimates were used in meta-analysis using 
Metasoft74 to assess the tissue-specificity of each variant–gene pair. For each vari-
ant–gene pair tested, Meta-Tissue estimates a global P value of association and the 
posterior probability that an effect exists in a tissue (m value). For computational 
feasibility, the Markov chain Monte Carlo (MCMC) method was used to approxi-
mate the exact solution.
Hierarchical agglomerative clustering was performed on trans-eGenes (50% 
FDR) and cis-eGenes (5% FDR) using distance metric (1 – Spearman’s ρ) of Meta-
Tissue effect sizes across all observed genes between tissue pairs. To supplement 
this analysis, we also performed multi-tissue analysis using 1) replication analysis 
(Extended Data Fig. 7); 2) hierarchical FDR control17 for both cis and trans analysis 
(Supplementary Information 8); and 3) an empirical Bayes approach18.
Allele-specific expression. For each sample, allele-specific RNA-seq 
read counts were generated at all heterozygous variants with the GATK 
ASEReadCounter tool75. Only uniquely mapping reads with a base quality 
≥ 10 at the variant were counted, and only those variants with coverage of 
at least eight reads were reported. Variants that met any of the following 
criteria were flagged and removed from downstream analyses: 1) UCSC 50-mer 
mappability of < 1; 2) simulation-based evidence of mapping bias76; and 3) 
heterozygous genotype not supported by RNA-seq data across all samples for 
that donor and no significant (FDR > 1%) evidence that the variant is monoal-
lelic in expression data75. Gene level measurements of haplotype expression were 
calculated by aggregating counts per sample across all heterozygous variants with 
ASE data within the gene using population phasing. Full ASE data are available 
through dbGaP.
Functional enrichment. We annotated discovered eVariants using chromatin state 
predictions from 128 cell types or cell lines sampled by the Roadmap Epigenomics 
project2. Genome segmentation was performed for each cell type or cell line using 
a 15-state hidden Markov model (HMM) over 400 bp windows. Several of the 
learned states are labelled as enhancers, promoters, and repressed regions. For 
the standard 15-state Roadmap segmentations, regulatory elements are labelled 
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independently for each cell type. For enrichment analyses, we constructed back-
ground variants sets that matched eVariants to randomly selected variants based 
on chromosome, distance to nearest TSS, and MAF.
trans-eQTL analysis was restricted to protein-coding genes and to GTEx tissues 
that are composed of at least one Roadmap Epigenomics cell type (26 tissues), 
which included 85 eVariants and 23 eGenes (10% FDR). We quantified enrichment 
of the trans variants relative to random variants in both enhancer and promoter 
elements in the GTEx discovery tissue’s matched Roadmap cell type (Extended Data 
Table 4). We then performed the same analysis with randomly matched cis-eGenes. 
Matching cis-eGenes were selected as follows: for each of the 23 trans-eGenes g, 
each having Ng associated eVariants (10% FDR), we randomly selected a cis-eGene 
that also had at least Ng associated variants (10% FDR). We then selected the top 
Ng variants associated with this gene based on P value. We then performed the 
same analysis using random sets of the strongest cis-eGenes, rather than random 
eGenes. Matching the strongest cis-eGenes was performed as follows: for each of 
the 23 trans-eGenes g, each having Ng associated eVariants (10% FDR), we ran-
domly selected a cis-eGene amongst the ten strongest cis-eGenes in that tissue, 
based on the P value of the strongest associated variant that also had at least Ng 
associated variants (10% FDR). We then selected the top Ng associated variants 
with this gene based on P value. Selecting 23 random cis-eGenes a single time 
yields unstable results, so we ran cis-eGene selection and enrichment 70 times 
with different selections. This was done for both random cis-eGenes and random 
selections amongst the strongest cis-eGenes. We rank-ordered the 70 trials for 
both promoters and enhancers based on average odds ratio enrichment relative 
to background. We then used the trial that was closest to median rank for plotting 
both promoter and enhancer enrichment results.
For piRNA enrichment analysis, we obtained a list of 6,250 piRNA clusters that 
were experimentally determined from RNA sequencing of human testis34. When 
considering all unique trans-eVariants identified in all tissues, we identified an 
enrichment of trans-eQTLs overlapping a piRNA cluster (17.8%) compared to the 
null expectation that trans-eVariants are randomly distributed relative to piRNA 
clusters (2.5%). To further establish the statistical significance of this observation, 
we generated a null distribution of piRNA-eVariant overlap by permutation. Using 
bedtools277, we permuted the location of piRNA clusters on the human genome 
10,000 times, requiring the piRNA clusters to be excluded from centromeres and 
sex chromosomes. We also evaluated the proportion of trans-eVariants located 
within 10 kb of a piRNA cluster, and estimated the significance of this enrichment 
using the same permutation scheme.
Co-localization of GWAS and eQTL associations. In order to assess the proba-
bility that molecular traits as estimated by cis- and trans-eQTLs and physio logical 
traits as estimated by GWAS share the same causal variant, we applied the coloc 
R package43. For each GWAS, we approximated the number of independent loci 
by extracting variants with at least genome-wide significance (P < 5 × 10−8) and 
farther than 1 Mb away from all other variants of higher statistical significance. 
For each genome-wide significant variant, we extracted the list of all eGenes 
(q < 0.05 for cis-eGene) within 1 Mb for coloc analyses. For each eGene, we 
excluded any variants without either eQTL or GWAS association statistics (effect 
size estimate, standard error and P value). We obtained reference information 
such as MAF, sample size and case-to-control proportions (in case of binary 
traits) for each variant whenever available; otherwise, study-wide estimate 
was used as a proxy. We defined a region or an eGene as having evidence of 
co-localization when region- or gene-based posterior probability of co-localization 
> . .
+
0 9PP4
PP3 PP4
Data and biospecimen availability. Genotype data from the GTEx v6p release 
are available in dbGaP (study accession phs000424.v6.p1; https://www.ncbi.nlm.
nih.gov/projects/gap/cgi-bin/study.cgi?study_id= phs000424.v6.p1). The VCFs 
for the imputed array data are available through dgGAP, in phg000520.v2.GTEx 
MidPoint Imputation.genotype-calls-vcf.c1.GRU.tar (the archive contains a VCF 
for chromosomes 1-22 and a VCF for chromosome X). Allelic expression data 
are also available in dbGaP. Expression data (read counts and RPKM) and eQTL 
input files (normalized expression data and covariates for 44 the tissues) from 
the GTEx v6p release are available from the GTEx Portal (http://gtexportal.org). 
Expression QTL results are available from the GTEx Portal. In addition to results 
tables for the 44 tissues in this study (eGenes, significant variant–gene pairs, and 
all variant–gene pairs tested), the portal provides multiple interactive visualization 
and data exploration features for eQTLs, including:
• eQTL box plot: displays variant-gene associations
• Gene eQTL visualizer: displays all significant associations for a gene across tissues 
and linkage disequilibrium information
• Multi-tissue eQTL plot: displays multi-tissue posterior probabilities from 
meta-analysis against single-tissue association results
• IGV browser: displays eQTL, across tissues and GWAS catalogue results for a 
selected genomic region
Residual biospecimens are available to all researchers according to the 
Genotype-Tissue Expression (GTEx) project biospecimens access policy. The 
policy and related forms can be found on the GTEx Portal under the Biobank tab.
Code availability. Software used to process the RNA-seq, genotypes, cis-eQTLs, 
and ASE is available at: https://github.com/broadinstitute/gtex-pipeline.
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Extended Data Figure 1 | Association of known covariates with 
expression components removed by PEER. Each cell depicts the 
adjusted (R2) between a pair of variables. Scale bar specific to each panel 
is displayed at the bottom. Grey cells represent pairs of variables without 
sufficient data to estimate correlation. a, For each tissue, adjusted (R2) 
reflecting the proportion of variance explained by each covariate of the 
entire PEER component removed from the expression data. A selected set 
of the most relevant sample-specific covariates is shown here. b, For each 
tissue, adjusted (R2) reflecting the proportion of variance explained by 
each covariate of the entire PEER component removed from the expression 
data. A selected set of the most relevant donor-specific covariates is shown 
here. See Supplementary Information for complete set of covariates. 
c, Adjusted R2 between each PEER factor and known sample covariates 
in skeletal muscle. d, Adjusted R2 between each PEER factor and known 
donor covariates in skeletal muscle.
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Extended Data Figure 2 | Controlling the discovery of cis- and trans-
eGenes. a, b, The number of unique cis- (a) and trans-eGenes (b) across all 
tissues at varying FDR thresholds. c, The per cent change in the number of 
cis-eGene discoveries comparing FDR (Storey’s q value) calculated across 
all tested genes in each tissue to FDR calculated only across autosomal 
lincRNA and protein-coding genes. Results are shown for each tissue and 
are stratified by gene type. The per cent change for each tissue and gene 
type is calculated as 100 × (no. of cis-eGenes from q value on the restricted 
gene set − no. of cis-eGenes from q value on all tested genes)/(no. of  
cis-eGenes from q value on all tested genes). d, The per cent change in the 
number of cis-eGene discoveries comparing q value and the Benjamini–
Hochberg (BH) procedure applied to all tested genes in each tissue. The 
percent change for each tissue and gene type is calculated as 100 × (no. of 
cis-eGenes from BH − no. of cis-eGenes from q value)/(no. of cis-eGenes 
from q value). Box plots depict the IQR, whiskers depict 1.5× IQR.
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Extended Data Figure 3 | Properties of cis-eGenes and non-eGenes. In 
these analyses, ‘non-eGenes’ refers to the set of genes with no significantly 
associated cis-eQTLs. a, Density of expression (mean across samples, 
median across tissues, in log10 scale) for cis-eGenes and non-eGenes. The 
difference in mean expression for cis-eGenes and non-eGenes is significant 
(Wald test; P < 1 × 10−16). b, Box plots comparing the probability of being 
loss-of-function-intolerant (pLI) scores41 for cis-eGenes and non-eGenes, 
stratified by expression percentile across all genes (mean across samples, 
median across tissues, in log10 scale). On average, highly expressed non-
eGenes have higher pLI scores than highly expressed cis-eGenes (t-test 
for the difference in mean pLI score between cis-eGenes and non-eGenes; 
BH adjusted P = 8.3 × 10−4 and 2.1 × 10−9 for (50,75]% and (75,100]%, 
respectively) and lowly expressed non-eGenes (t-test for the difference 
in mean pLI score between highly and lowly expressed non-eGenes; BH 
adjusted P ≤ 7.8 × 10−46, P ≤ 5.5 × 10−17 and P ≤ 2.1 × 10−3 for (75,100]% 
vs [0,25]%, (75,100 vs (25,50]% and (75,100]% vs (50,75]%, respectively). 
c, Gene Ontology (GO) analysis of tested protein-coding non-eGenes. 
We used the PANTHER overrepresentation test78 (release 20160715) 
against 20,972 human genes as background to test for enrichment in GO 
biological processes using the GO database release 2017-02-28. Significant 
GO IDs (Bonferroni adjusted P < 0.05) were selected for analysis with 
REVIGO79 to group similar ontological terms, which yielded 22 over-
represented GO IDs. d, GO analysis of a more stringent set of protein-
coding non-eGenes. Selected genes included those not tested in GTEx 
(532 genes) or those with a minimum nominal P value across tissues 
greater than 0.1 (692 genes). Of these stringent 1,224 non-eGenes, 808 
were mapped in the GO analysis. Using a similar approach as in c, 20 over-
represented GO IDs were identified. For both c and d, the x-axis represents 
the − log10 P value resulting from GO analysis. GO IDs are coloured by the 
broader enrichment category to which each corresponds. Box plots depict 
the IQR, whiskers depict 1.5× IQR.
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Extended Data Figure 4 | Identification of cis-acting eQTLs using 
allele-specific expression at chromosome-wide distances. a, A logistic 
regression based model was developed to predict the probability 
of phasing error as a function of distance and variant minor allele 
frequencies. When applied to chromosome 2 of 1000 Genomes sample 
NA12878, this model had a receiver operating characteristic (ROC) area 
under the curve (AUC) of 0.87 using population phasing compared to 
transmission phasing. b, ROC when applying the beta-binomial mixture 
model to detect cis-acting regulation to the GTEx v6p subcutaneous 
adipose cis-eQTLs, with an AUC of 0.88. As the null, eGenes were shuffled 
with respect to eVariants. c, Power analysis using all nominally significant 
(P < 1.0 × 10−5) linkage disequilibrium pruned associations within 100 kb 
of the TSS illustrating the number of eQTLs with nominally significant 
(P ≤ 0.01) evidence of cis-regulation as a function of phasing error and 
eQTL effect size. Expression QTL effect size was calculated using a 
companion method28, and uniform phasing error between 0 and 100% was 
introduced in silico. d, Proportion of nominally significant (P < 1.0 × 10−5) 
linkage disequilibrium-pruned intrachromosomal eQTLs with nominally 
significant (P ≤ 0.01) ASE supported evidence of cis regulation in bins 
of increasing TSS distance. Observed indicates what is seen in the data, 
while Max Error indicates what would be expected in the worst-case 
scenario of phasing error (50%). e, Example of significant ASE supported 
cis-regulation at a distance of 52.7 Mb between eVariant rs17494053 
and eGene ENSG00000108509 in whole blood. Each point represents 
allelic imbalance in a single eVariant homozygote (circle) or heterozygote 
(triangle). 
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Extended Data Figure 5 | Effects of sample size and assayed tissues on 
cis-eGene discovery. a, Number of significant cis-eGenes at 5% FDR  
(y-axis) discovered in 44 GTEx tissues versus sample size (x-axis).  
b, Number of significant eGenes at FDR 5% (y-axis) discovered in nine 
GTEx tissues each subsampled to various sizes where possible (n = 70, 100, 
125, 150, 175, 200, 225, 250, 275, 300, 325, and 350; x-axis). We computed 
the number of cis-eGenes at each subsample size (circles connected by 
lines). We also plotted the number of cis-eGenes discovered with no 
subsampling of donors (diamonds). c, Number of significant cis-eGenes at 
FDR 5% (y-axis) as a function of sample size and number of tissues assayed 
(x-axis). Each tissue was subsampled to 70, 100, 150, 200, and 250 donors, 
and a forward search was used to assess sequential combinations of tissues 
that maximize the total number of unique cis-eGenes discovered.
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Extended Data Figure 6 | Measuring cis-regulatory variation using ASE. 
a, Proportion of protein-coding genes with ASE data in at least one tissue 
as a function of donors (top row) and with significant imbalance (binomial 
test versus 0.5, 5% FDR) stratified by ASE effect size (| log2(hapa count/
hapb count)| ) deciles. Gene-level measurements of haplotype expression 
were calculated by aggregating counts per sample across all heterozygous 
variants with ASE data within the gene using population phasing. The 
following filters were applied on ASE data: total coverage ≥ 8 reads, no 
mapping bias in simulations76, UCSC mappability > 50, and no significant 
(FDR > 1%) evidence that variant is monoallelic in expression data75. 
b, log2 transformed cis-eQTL effect size (x-axis) versus log2 transformed 
ASE effect size (y-axis) for whole blood (Spearman’s ρ = 0.82) and 
c, subcutaneous adipose (Spearman’s ρ = 0.74).
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Extended Data Figure 7 | Replication of cis-eQTLs between tissues. 
a, π1 statistics for cis-eQTLs are reported for all pairwise combinations 
of discovery (y-axis) and replication (x-axis) tissues. Higher π1 values 
indicate a stronger replication signal. Tissues are grouped using 
hierarchical clustering on rows and columns separately with a distance 
metric of 1 − ρ, where ρ is the Spearman’s correlation coefficient of π1 
values. π1 is calculated only when the gene is expressed and testable in 
the replication tissue. b, c, π1 replication is reported between tissues 
subsampled down to 70 non-matched (b) and matched (c) donors. In 
(c), grey tiles indicate tissue pairs with fewer than 70 shared donors. 
d, Effect of sample size (x-axis) on average π1 replication (y-axis) across 
all replication tissues. e, Scatter plot of π1 scores among tissue pairs with 
matched (x-axis) and non-matched (y-axis) donors.
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Extended Data Figure 8 | See next page for caption.
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Extended Data Figure 8 | Tissue-specificity of cis- and trans-eQTLs. 
a, Sharing of independently identified cis-eGenes across the 44 GTEx 
tissues (cis-eGenes are independently identified in each of the 44 
tissues and then binned by the number of tissues in which they appear). 
b, Sharing of cis-eGenes across 44 GTEx tissues that were identified using 
the hierarchical multi-tissue analysis. c, The prior probabilities of having 
significant variant–gene association in different numbers of tissues, 
calculated using an empirical Bayes model. The prior probabilities are 
summed up on the basis of the Hamming weights of the corresponding 
cis-eQTL configurations. d–g, Meta-analysis performed using Meta-Tissue 
for trans-eGenes (50% FDR), randomly selected cis-eGenes (50 % FDR), 
and an equal number of the top cis-eGenes by P value. Distribution of the 
number of tissues that have Meta-Tissue m values greater than a given 
threshold (d, 0.5; e, 0.6; f, 0.9) across variant–gene pairs that have an 
effect (based on m value thresholding) in at least one tissue. g, The same 
distribution as d except that variant–gene pairs with predicted effect in 
zero tissues (based on the number of m values > 0.5) are included. Meta-
Tissue predicts that many cis-eGenes (50% FDR) and trans-eGenes (50% 
FDR) will have an effect in zero tissues. The number of zero predictions 
is largely reduced for the top most significant cis-eGenes. h, Distribution 
of observed replication rate between pairs of tissues for trans-eQTLs 
(10% FDR) versus the predicted replication rate for trans-eQTLs (10% 
FDR) based on a negative binomial generalized linear model trained on 
cis-eQTLs (10% FDR0.1). This model directly accounts for effect size 
and minor allele frequency. Replication rates shown for a range of FDR 
thresholds in replication tissue. Box plots depict the IQR, whiskers depict 
1.5× IQR.
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Extended Data Figure 9 | Examples of trans-eQTLs shared across 
tissues. a, An example of a trans-eQTL (rs7683255–NUDT13) originally 
identified in sun-exposed skin (10%, P ≤ 1.1 × 10−10, indicated by asterisk) 
that has a global effect across tissues. The lines represent 95% confidence 
intervals of the effect sizes. A thicker line indicates that this variant–gene 
pair is called significant at P ≤ 0.05 in the corresponding tissue. b, An 
example of a trans-eQTL (rs60413914–RMDN3) that is genome-wide 
significant in putamen (basal ganglia) (10% FDR, P ≤ 1.2 × 10−13, 
indicated by asterisk) that has an effect in all five brain tissues tested but 
shows little effect in other tissues. c, Expression levels (RPKM) of RMDN3 
in all donors across 44 tissues. Box plots depict the IQR, whiskers depict 
1.5× IQR.
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Extended Data Figure 10 | See next page for caption.
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Extended Data Figure 10 | Sharing information across tissues for  
cis-eQTLs. a, The proportion of expressed genes for which cis-eGenes are 
discovered in single tissues (5% FDR; origin) and the multi-tissue meta-
analysis (m > 0.9; arrow), stratified by the sample size of individual tissues. 
In the meta-analysis, cis-eQTL discoveries are made using Meta-Tissue to 
identify tissues where the posterior probability a given cis-eQTL effect 
exists (that is, the tissue’s m value for the variant) is > 0.9. b, The 
proportion of expressed genes that had a cis-eQTL in the subsampled data 
(n = 70) is shown on the y-axis, and the actual sample size of the tissue is 
shown on the x-axis. The proportion is shown for the tissue-by-tissue 
approach (5% FDR; origin) and using Meta-Tissue (m > 0.9; arrow).  
c, For each of the subsampled tissue data sets (n = 70), we identified the 
additional K discoveries that were made using Meta-Tissue but were not 
significant at the 5% FDR threshold in the tissue-by-tissue analysis; we 
then identified the K most significant cis-eQTLs in the tissue-by-tissue 
analysis with a q value greater than 5% representing the additional 
discoveries we would make by simply relaxing the FDR. We then 
compared these two sets of K cis-eQTLs to the list of significant cis-eQTLs 
found in the full tissue-by-tissue analysis by calculating the proportion of 
the K cis-eQTLs that were significant in the full analysis (y-axis). The 
tissues are ordered along the x-axis by increasing sample size in the actual 
data set. d, The proportion of annotated and expressed genes that were 
found to be eGenes using the tissue-by-tissue approach and the 
hierarchical selection procedure implemented by TreeQTL.  
e, The number of cis-eGene discoveries per tissue (y-axis) against sample 
size (x-axis). The number of discoveries for the tissue-by-tissue approach 
are represented by the origin of each segment, while the number of 
discoveries from the hierarchical selection procedure are shown as arrows. 
As with Meta-Tissue, the hierarchical procedure improves cis-eGene 
discovery for tissues with low sample sizes, albeit fewer tissues overall have 
the benefits of this effect. Furthermore, an outcome of this procedure is 
that for tissues with high sample sizes, reported numbers of cis-eGenes are 
more conservative than those observed in the tissue-by-tissue analyses or 
Meta-Tissue. f, Improvement of cis-eGene discovery by incorporating 
genomic annotations. For the 26 tissues for which we can relate cell-type 
specific chromHMM annotations, we identify cis-eGenes accounting for 
the variant-level genomic annotations and corresponding enrichment 
estimates using the Bayesian FDR control procedure described 
previously80. For each tissue, the number of cis-eGenes identified by the 
Bayesian procedure (arrow) is plotted against the tissue-by-tissue results 
(origin).
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Extended Data Figure 11 | cis effect size analyses. a, For each autosomal 
protein-coding and lincRNA cis-eGene with eVariants discovered 
independently in at least five tissues, the median effect size was computed 
across these tissues. The empirical cumulative distribution function 
(CDF) of these median effect sizes is depicted. b, Normalized effect sizes 
of cis-eVariants located upstream of the gene, within the transcript, and 
downstream of the gene. c, cis-eQTL effect distributions stratified by 
discovery tissue. Tissues are sorted from largest sample size (muscle-
skeletal, n = 361) to the smallest (uterus, n = 70). Box plots depict the IQR, 
whiskers depict 1.5× IQR.
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Extended Data Figure 12 | trans-eQTL discovery restricted to informed 
subsets. a, Quantile–quantile (QQ) plot of trans-eQTL P values from all 
variants (x-axis) and the subset of trans-eQTL P values restricted to  
cis-eVariants (y-axis), illustrating enrichment of low trans-eQTL 
association P values for cis-eVariants. Data are plotted separately 
for skeletal muscle (pale blue) and adipose (red). trans-eQTLs with 
FDR ≤ 10% are shown as large circles, those with FDR > 10% are shown as 
small circles. b, QQ plot of trans-eQTL P values from all variants  
(x-axis) and the subset of trans-eQTL P values restricted to GWAS 
associated variants (y-axis), illustrating enrichment of low trans-eQTL 
association P values for cis-eVariants. Data are plotted separately for 
skeletal muscle (pale blue) and lung (green). trans-eQTLs with  
FDR ≤ 10% are shown as large circles, those with FDR > 10% are shown as 
small circles.
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Extended Data Figure 13 | Replication of cis-eQTLs in TwinsUK data. 
a, All cis-eQTLs (5% FDR) from six tissues (adipose, subcutaneous; 
adipose, visceral omentum; cells, EBV-transformed lymphocytes; skin, 
not sun-exposed; skin, sun-exposed; and whole blood) were examined 
for replication in four closely matched tissues (LCLs, skin, whole blood, 
subcutaneous adipose) from the TwinsUK data. For each tissue pair 
(in facets), replication P value histograms illustrate strong enrichment 
of small P values. π1 statistics are provided for each tissue pair. b, All 
trans-eVariant–eGene pairs (10% FDR) from all tissues were examined 
for replication in four closely matched tissues (LCLs, skin, whole blood, 
subcutaneous adipose) from the TwinsUK data. Observed replication 
P values (y-axis) are plotted against the expected uniform P value 
distribution under the null hypothesis (x-axis). Replication P values are 
plotted separately for matched (grey) and unmatched (black) tissue pairs.
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Extended Data Figure 14 | Disease gene enrichment for tissue-specific and shared cis-eQTLs. Enrichment of shared and tissue-specific cis-eGenes 
in different disease gene data sets. Enrichments and 95% CI in each data set are calculated via Fisher’s exact test, and the odds ratio is plotted after log10 
transformation.
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Extended Data Figure 15 | General and replicated per-variant cis-
eGene associations across tissues. a, Distribution of the number of 
unique cis-eGenes per variant within each tissue (points) or in the union 
of variant–eGene associations across all tissues. b, Proportion of variants 
with top-associated gene preserved between tissues for varying effect 
size thresholds, across all pairwise tissue comparisons. c, Proportion of 
variants with top-associated gene preserved between tissues for varying 
nominal P value thresholds, across all pairwise tissue comparisons. Red 
distributions include all variants with an associated cis-eGene in one of the 
two compared tissues, and blue distributions require the variant to have 
at least two associated cis-eGenes in each tissue. Distributions for which 
more than half of the pairwise comparisons (points) are empty are not 
shown.
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Extended Data Figure 16 | Broad trans-regulatory locus 9q22 in 
thyroid tissue. a, FOXE1 expression is thyroid-specific. b, Correlation 
between FOXE1 expression levels and thyroid PEER factors, compared 
to 100 random genes. For every gene, absolute correlation was sorted in 
decreasing order. The correlation of FOXE1 with the fifth, sixth, seventh 
and eighth PEER factors was significantly higher than the correlation of 
random genes at those rank ordered PEER factors (empirical P ≤ 0.05).  
c–e, Variants in the chr 9q22 locus were enriched for association with 
genes on other chromosomes in thyroid carcinomas compared to 
randomly selected variants nearby randomly selected genes. We used 
variants that were found within 35 kb upstream or downstream of the 
gene TSS. f, rs10759975 is associated with trans-eGene TMEM253. 
g, rs10759975 is associated with trans-eGene ARFGEF3. h, rs10759975 
shows cis association with TRMO. i, rs10759975 is weakly associated in cis 
with FOXE1. Box plots depict the IQR, whiskers depict 1.5× IQR.
© 2017 Macmillan Publishers Limited, part of Springer Nature. All rights reserved.
ArticlereSeArcH
Extended Data Figure 17 | Trait-associated variants in skeletal muscle near interferon regulatory factor IRF1. a, rs1012793 has broad regulatory 
impact in skeletal muscle. b, Gene set enrichment for potential trans-eGene targets (identified at P ≤ 0.001) of skeletal muscle 5q31 locus.
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Extended Data Table 1 | trans-eVariant and trans-eGene discoveries for genome-wide FDr control, and trans-eGene discoveries for gene-
level FDr control
Each tissue with non-zero values is included as a row; the columns include the number of samples for that tissue, followed by the number of unique trans-eGenes and trans-eVariants identified in the 
genome-wide tests, and the number of unique trans-eGenes found using gene-level FDR calibration (Supplementary Information 8). Ultimately, the set of 673 trans-eQTLs identified in the genome-wide 
approach yielded 602 unique trans-eVariants.
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Extended Data Table 2 | Distal (>5 Mb) intra-chromosomal eQTLs across the GTEx tissues
Only tissues with at least one distal intra-chromosomal eQTL are listed.
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Extended Data Table 3 | trans-eVariant and trans-eGene discoveries with hierarchical FDr control
Only tissues with non-zero discoveries are shown. The three-level hierarchical procedure (see Methods) performs FDR control across tissues. More specifically, it controls the FDR of eVariants, the 
average proportion of false variant-gene associations across all eVariants, and a weighted average of false tissue discoveries for the selected variant-gene pairs (weighted by the size of the eVariant and 
eGene sets). The procedure was applied after linkage disequilibrium pruning.
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Extended Data Table 4 | GTEx tissue mapping with Epigenomics roadmap cell types
© 2017 Macmillan Publishers Limited, part of Springer Nature. All rights reserved.
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Nature Research wishes to improve the reproducibility of the work that we publish. This form is intended for publication with all accepted life 
science papers and provides structure for consistency and transparency in reporting. Every life science submission will use this form; some list 
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`    Experimental design
1.   Sample size
Describe how sample size was determined. eQTL discovery power calculations were described in a previous publication by the 
GTEx consortium: PMID: 23715323.
2.   Data exclusions
Describe any data exclusions. Numerous samples were excluded from eQTL analyses because they came from 
diseased tissues, failed quality control, etc. We explicitly define all exclusion criteria 
in the Methods.
3.   Replication
Describe whether the experimental findings were 
reliably reproduced.
Cis and trans eQTLs were replicated in the TwinsUK cohort, as described in the text.
4.   Randomization
Describe how samples/organisms/participants were 
allocated into experimental groups.
Order of sample processing for library preparation and sequencing was 
randomized to avoid batch effects.
5.   Blinding
Describe whether the investigators were blinded to 
group allocation during data collection and/or analysis.
No blinding took place.
Note: all studies involving animals and/or human research participants must disclose whether blinding and randomization were used.
6.   Statistical parameters 
For all figures and tables that use statistical methods, confirm that the following items are present in relevant figure legends (or in the 
Methods section if additional space is needed). 
n/a Confirmed
The exact sample size (n) for each experimental group/condition, given as a discrete number and unit of measurement (animals, litters, cultures, etc.)
A description of how samples were collected, noting whether measurements were taken from distinct samples or whether the same 
sample was measured repeatedly
A statement indicating how many times each experiment was replicated
The statistical test(s) used and whether they are one- or two-sided (note: only common tests should be described solely by name; more 
complex techniques should be described in the Methods section)
A description of any assumptions or corrections, such as an adjustment for multiple comparisons
The test results (e.g. P values) given as exact values whenever possible and with confidence intervals noted
A clear description of statistics including central tendency (e.g. median, mean) and variation (e.g. standard deviation, interquartile range)
Clearly defined error bars
See the web collection on statistics for biologists for further resources and guidance.
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`   Software
Policy information about availability of computer code
7. Software
Describe the software used to analyze the data in this 
study. 
The GTEx eQTL pipeline is available at https://github.com/broadinstitute/gtex-
pipeline
For manuscripts utilizing custom algorithms or software that are central to the paper but not yet described in the published literature, software must be made 
available to editors and reviewers upon request. We strongly encourage code deposition in a community repository (e.g. GitHub). Nature Methods guidance for 
providing algorithms and software for publication provides further information on this topic.
`   Materials and reagents
Policy information about availability of materials
8.   Materials availability
Indicate whether there are restrictions on availability of 
unique materials or if these materials are only available 
for distribution by a for-profit company.
NA
9.   Antibodies
Describe the antibodies used and how they were validated 
for use in the system under study (i.e. assay and species).
NA
10. Eukaryotic cell lines
a.  State the source of each eukaryotic cell line used. NA
b.  Describe the method of cell line authentication used. NA
c.  Report whether the cell lines were tested for 
mycoplasma contamination.
NA
d.  If any of the cell lines used are listed in the database 
of commonly misidentified cell lines maintained by 
ICLAC, provide a scientific rationale for their use.
NA
`    Animals and human research participants
Policy information about studies involving animals; when reporting animal research, follow the ARRIVE guidelines
11. Description of research animals
Provide details on animals and/or animal-derived 
materials used in the study.
NA
Policy information about studies involving human research participants
12. Description of human research participants
Describe the covariate-relevant population 
characteristics of the human research participants.
The human research participants are described in detail in the text and methods.
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Erratum
doi:10.1038/nature25160
Erratum: Genetic effects on gene 
expression across human tissues
GTEx Consortium 
Nature 550, 204–213 (2017); doi:10.1038/nature24277
In the HTML version of this Article, the GTEx Consortium author 
list shown underneath the title was incorrectly displayed as: ‘GTEx 
Consortium, Lead analysts:, Laboratory, Data Analysis & Coordinating 
Center (LDACC):, NIH program management:, Biospecimen 
collection:, Pathology:, eQTL manuscript working group:, Alexis 
Battle, Christopher D. Brown, Barbara E. Engelhardt & Stephen 
B. Montgomery’ instead of ‘GTEx Consortium’ (with a link to the 
complete author list at the bottom of the page). This has been corrected 
online.
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